NLNico Lieffering

Nico Lieffering

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nico Lieffering has a total of 69 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Pathogenic Variants in RNU2‐2 , a Non‐coding Spliceosomal RNA , Cause a Distinctive Developmental and Epileptic Encephalopathy

    by Annie T.G. Chiu, Mark F. Bennett, Harshini Thiyagarajah, Amy L. Schneider, Sian M.W. Macdonald, Tom Witkowski, Edith P Almanza Fuerte, Talia J. Allan, Nico Lieffering, Blake Robinson, et al.

    RNU2‐2 is a non‐coding small nuclear RNA (snRNA) that forms part of the spliceosome. We identified recurrent pathogenic RNU2‐2 variants in 4 of 672 (0.6%) patients with developmental and epileptic encephalopathies (DEEs) of unknown cause. An additional patient was subsequently included. Patients with RNU2‐2 DEE had median seizure onset age of 24 months, focal and generalized seizures, status epilepticus ( n = 5), severe to profound impairment, hyperventilation ( n = 3), and obstructive sleep apnea ( n = 3). Electroencephalography showed sleep‐activated multifocal epileptiform discharges ( n = 4) and hippocampal sclerosis on magnetic resonance imaging ( n = 3). Pathogenic variants in RNU2‐2 cause a distinctive severe DEE.SnRNAs are emerging as an important cause of genetic DEEs. ANN NEUROL 2026;99:51–58


  • Open Access

    Diagnostic utility of DNA methylation analysis in genetically unsolved pediatric epilepsies and CHD2 episignature refinement

    by Christy W. LaFlamme, Cassandra Rastin, Soham Sengupta, Helen E. Pennington, Sophie J. Russ-Hall, Amy L. Schneider, Emily S. Bonkowski, Edith P. Almanza Fuerte, Talia J. Allan, Miranda Perez-Galey Zalusky, et al.

    Sequence-based genetic testing identifies causative variants in ~ 50% of individuals with developmental and epileptic encephalopathies (DEEs). Aberrant changes in DNA methylation are implicated in various neurodevelopmental disorders but remain unstudied in DEEs. We interrogate the diagnostic utility of genome-wide DNA methylation array analysis on peripheral blood samples from 582 individuals with genetically unsolved DEEs. We identify rare differentially methylated regions (DMRs) and explanatory episignatures to uncover causative and candidate genetic etiologies in 12 individuals. Using long-read sequencing, we identify DNA variants underlying rare DMRs, including one balanced translocation, three CG-rich repeat expansions, and four copy number variants. We also identify pathogenic variants associated with episignatures. Finally, we refine the CHD2 episignature using an 850 K methylation array and bisulfite sequencing to investigate potential insights into CHD2 pathophysiology. Our study demonstrates the diagnostic yield of genome-wide DNA methylation analysis to identify causal and candidate variants as 2% (12/582) for unsolved DEE cases.


  • Open Access

    SCN8A self‐limited infantile epilepsy: Does epilepsy resolve?

    by Emma Young, Rebekah Harris, Nico Lieffering, Guillem de Valles‐Ibáñez, Denis Nyaga, Mark F. Bennett, Michael S. Hildebrand, Ingrid E. Scheffer, Lynette G. Sadleir

    SCN8A variants cause a spectrum of epilepsy phenotypes ranging from self‐limited infantile epilepsy (SeLIE) to developmental and epileptic encephalopathy. SeLIE is an infantile onset focal epilepsy, occurring in developmentally normal infants, which often resolves by 3 years. Our aim was to ascertain when epilepsy resolves in SCN8A‐SeLIE. We identified unpublished individuals with SCN8A‐SeLIE and performed detailed phenotyping. Literature was searched for published SCN8A‐SeLIE cases. Nine unpublished individuals from four families were identified (age at study = 3.5–66 years). Six had their last seizure after 3 years (range = 4–21 years); although drug‐responsive and despite multiple weaning attempts (1–5), five of six remain on antiseizure medications (carbamazepine, n = 3; lamotrigine, n = 2). We identified 29 published individuals with SCN8A‐SeLIE who had data on seizure progression. Of the 22 individuals aged at least 10 years, reported here or in the literature, nine of 22 (41%) had seizure offset prior to 3 years, five of 22 (23%) had seizure offset between 3 and 10 years, and eight of 22 (36%) had seizures after 10 years. Our data highlight that more than half of individuals with SCN8A‐SeLIE continue to have seizures into late childhood. In contrast to SeLIE due to other etiologies, many individuals have a more persistent, albeit drug‐responsive, form of epilepsy.